These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 6598941)

  • 1. [Small doses of ARA-C in the treatment of myeloblastic leukemia and blast crisis of myelocytic leukemia].
    Górski J; Kicińska M; Cenian E
    Acta Haematol Pol; 1984; 15(3-4):167-70. PubMed ID: 6598941
    [No Abstract]   [Full Text] [Related]  

  • 2. [High doses of cytosine arabinoside in the treatment of refractory leukemia].
    Klener P; Háber J; Kolesková E
    Sb Lek; 1987 Sep; 89(8-9):271-5. PubMed ID: 3478794
    [No Abstract]   [Full Text] [Related]  

  • 3. [Small dose of ARA-C in the treatment of an elderly patient with acute myeloblastic leukemia].
    Takeyama H; Yano K; Ohoshima K; Satake T; Emi N; Sugihara T; Kawashima K
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2418-22. PubMed ID: 6579883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
    Castagnola C; Nozza A; Corso A; Bernasconi C
    Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of myelocytic leukemia during blast transformation (preliminary report)].
    Frinovskaia IV; Bogomolova LV
    Sov Med; 1976 Aug; (8):28-32. PubMed ID: 1070163
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical, cytochemical and immunological characteristics of the blast crisis in myelocytic leukemia].
    Vygovskaia IaI; Loginskiĭ VE; Shnitsar EV; Mazurok AA
    Ter Arkh; 1983; 55(8):26-30. PubMed ID: 6579695
    [No Abstract]   [Full Text] [Related]  

  • 8. Extramedullary myeloblastic transformation of chronic myelocytic leukemia. Lymph node infiltration one year before marrow blastic change.
    Woodson DL; Bennett DE; Sears DA
    Arch Intern Med; 1974 Sep; 134(3):523-6. PubMed ID: 4527801
    [No Abstract]   [Full Text] [Related]  

  • 9. Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases.
    Zhang ZY; Hou CH; Zhu YF; You XY; Li JL; Fu Z
    Chin Med J (Engl); 1987 Jul; 100(7):565-8. PubMed ID: 3123163
    [No Abstract]   [Full Text] [Related]  

  • 10. [Results of the treatment of myeloblastic crisis in myelocytic leukemia using the HAR program].
    Zdziechowska H; Niemierko E; Takiel M; Konopka L; Pawelski S
    Acta Haematol Pol; 1986; 17(3-4):91-5. PubMed ID: 3473887
    [No Abstract]   [Full Text] [Related]  

  • 11. [Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
    Waage A; Hammerstrøm J; Lødemel B; Hoff JE; Langtind J
    Tidsskr Nor Laegeforen; 1986 Feb; 106(6):496-7. PubMed ID: 3457484
    [No Abstract]   [Full Text] [Related]  

  • 12. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preliminary results of the treatment of non-lymphoblastic leukemia and bone marrow dysplasia with small doses of cytosine arabinoside].
    Brodzki LM
    Acta Haematol Pol; 1985; 16(1-2):85-9. PubMed ID: 3914171
    [No Abstract]   [Full Text] [Related]  

  • 15. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cytosine-arabinoside in the treatment of acute myeloblastic leukemias].
    Maroncelli P; Canova R; Casalino C; Fischioni P
    Minerva Med; 1971 Mar; 62(21):1110-9. PubMed ID: 5279670
    [No Abstract]   [Full Text] [Related]  

  • 18. [A case of acute myelocytic leukemia in relapse controlled by continuous home administration of Ara-C].
    Takimoto Y; Imanaka F; Kouzai K; Okuhara T
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):495-8. PubMed ID: 8678505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Case of full remission of a blast crisis in myelocytic leukemia].
    Kondrak R; Wedrychowicz A
    Wiad Lek; 1981 Mar; 34(6):507-10. PubMed ID: 6943867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.